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This manuscript reviews current advances in the use of radioimmunotherapy (RIT) for the
treatment of B-cell non-Hodgkin’s lymphoma (NHL). RIT has been in use for more than
20 years and has progressed significantly with the discovery of new molecular targets, the
development of new stable chelates, the humanization of monoclonal antibodies (MAbs),
and the use of pretargeting techniques. Today, two products targeting the CD20 antigen
are approved: 131I-tositumomab (Bexxar®), and 90Y-ibritumomab tiuxetan (Zevalin®). 131I-
tositumomab is available in the United States, and 90Y-ibritumumab tiuxetan in Europe, the
United States, Asia, and Africa. RIT can be integrated in clinical practice using non-ablative
activities for treatment of patients with relapsed or refractory follicular lymphoma (FL) or as
consolidation after induction chemotherapy in front-line treatment in FL patients. Despite
the lack of phase III studies to clearly define the efficacy of RIT in the management of
B lymphoma in the era of rituximab-based therapy, RIT efficacy in NHL has been demon-
strated. In relapsing refractory FL and transformed NHL, RIT as a monotherapy induces
around 30% complete response with a possibility of durable remissions. RIT consolidation
after induction therapy significantly improves the quality of the response. Dose-limiting tox-
icity of RIT is hematological, depending on bone marrow involvement and prior treatment.
Non-hematological toxicity is generally low. Different studies have been published assess-
ing innovative protocols of RIT or new indications, in particular treatment in patients with
aggressive lymphomas. High-dose treatment, RIT as consolidation after different therapeu-
tic induction modalities, RIT in first-line treatment or fractionated RIT showed promising
results. New MAbs, in particular humanized MAbs, or combinations of naked and radiola-
beled MAbs, also appear promising. Personalized dosimetry protocols should be developed
to determine injected activity.
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INTRODUCTION
B-cell NHL can be classified into more than 25 histologi-
cal subtypes according to World Health Organization (WHO)
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; ASCT,
autologous stem-cell transplantation; BEAM, carmustine, etoposide, cytarabine,
melphalan; CDC, complement-dependent cytotoxicity; CR, complete response;
DLBCL, diffuse large B-cells NHL; DLT, dose-limiting toxicity; DR, duration of
response; EFS, event-free survival; FDG-PET, positron emission tomography with
18F-fluorodeoxyglucose; FL, follicular lymphoma; FLIPI, follicular lymphoma inter-
national prognostic index; GELF, Groupe d’Etude des lymphomes folliculaires;
HAMA, human anti-murine antibodies; HD, high-dose; HD, high-dose; IPI, inter-
national prognostic index; MAb, monoclonal antibodies; MCL, mantle cell lym-
phoma; MDS, myelodysplastic syndrome; MRD, minimal residual disease; MRD,
minimal residual disease; MTD, maximum tolerated dose; NHL, non-Hodgkin lym-
phoma; OR, objective response; OR, objective response; ORRs, overall response
rates; OS, overall survival; PFS, progression-free survival; PR, partial response;
R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone;
RIC, reduced-intensity conditioning; RIT, radioimmunotherapy; RIT-N, the inter-
national radioimmunotherapy network; SCT, stem-cell transplantation; TBI, total-
body irradiation; TTP, time to progression; WHO, World Health Organization.
classification, and can be separated into aggressive (65% of NHL)
and indolent forms (35%) (1). The Ann Arbor classification is
used for staging, including 1–4 stages. Diffuse large B-cell NHL
(DLBCL) is the most common type of aggressive NHL (31%), and
follicular lymphoma (FL) the most common type of indolent NLH
(22%). FL generally shows indolent progression with response
to chemotherapy, but always relapses. Survival ranges from 5 to
15 years, depending on the Follicular Lymphoma International
Prognostic Index (FLIPI) or Groupe d’Etude des Lymphomes Fol-
liculaires (GELF) prognosis score. Prognosis of DLBCL is different,
with 50–60% of patients being cured, with prognosis depend-
ing on the International Prognostic Index (IPI) score. Mantle cell
lymphoma (MCL) represents 6% of NHL and has a poor overall
survival (OS), with a median survival of about 5 years in young
patients, but often lower survival rates in elderly patients. Treat-
ment of disseminated NHL includes multi-agent chemotherapy,
with the possibility of high-dose (HD) chemotherapy coupled
with stem-cell transplantation (SCT) in high-risk young people
(<60–65 years). In patients with aggressive or indolent B-NHL,
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the introduction of rituximab (Mabthera®, Rituxan®, Roche Ltd.,
Genentech, Basel, Switzerland), a monoclonal chimeric anti-CD20
antibody, when combined with different chemotherapy regimens
(R-chemotherapy) resulted in an improvement in patient out-
come, compared with chemotherapy alone (2–4). Response rates
with rituximab alone is rather modest (5). Involved-field radia-
tion can be proposed for limited stage FL or treatment of residual
masses of DLBCL.
Radioimmunotherapy (RIT) is a targeted therapy whereby irra-
diation from radionuclides is delivered to tumor targets using
monoclonal antibodies (MAbs) directed to a tumor antigen (6, 7).
NHL cells express well-characterized antigens, are highly radiosen-
sitive, respond to cold mAbs, and represent a relevant indication
for RIT. In 1988, DeNardo et al. reported the first RIT clini-
cal trial in resistant NHL, using the anti-HLA-DR Lym-1 MAb
labeled with iodine-131 (8). Over the last 20 years, RIT has signifi-
cantly progressed with the development of new humanized mAbs,
stable chelates for labeling, and pretargeting techniques (9). The
cytotoxic mechanisms of RIT involve both radiobiological and
immunological processes (10). MAbs, particularly rituximab, may
exert cytotoxic effects through apoptosis, antibody-dependent
cell-mediated cytotoxicity (ADCC), and complement-dependent
cytotoxicity (CDC). When MAbs are labeled with radionuclides,
the combination of immunological and radiobiological cytotox-
icity, including bystander effects, results in higher anti-tumor
efficacy (10). RIT delivers continuous heterogeneous low-dose-
rate irradiation (<1 Gy/h) concomitant with biological effects
such as the repair of radiation-induced sublethal damage (10).
Fowler evaluated the effects of low-dose-rate on the relative effec-
tiveness of radiation as a function of the repair capacities of
tissues using a mathematical model (11). They conclude that
DNA repair lowers the efficacy of low-dose-rate irradiation, but
that this effect may be overcome in part by cell cycle arrest in
the G2/M phase, which makes cells more radiosensitive. However
this hypothesis is now challenged by other explanations such as
a decreased sensing of DNA damage by ATM at low-dose-rate
that results in decreased activation of the early DNA damage
response and repair (12). Other effect such as reoxygenation of
hypoxic cells during the irradiation and effects on tumor ves-
sels have been proposed to explain the relatively high efficacy
of RIT (10). It is most likely that a combination of these effect
and additional biological and immunological mechanisms are at
work to make RIT effective in lymphoma, in spite of the low-
dose-rate and low absorbed dose delivered by the therapeutic
approach.
Although a dose-effect relationship has not yet been clearly
demonstrated, it is likely to be present even if such a relationship
could be masked by the anti-tumor effects of cold MAbs that are
generally injected prior to the radiolabeled antibody. The choice of
appropriate antibodies and radionuclide is critical (13). The path-
length of penetration of the radioactive emission should match the
size of the targeted tumor. Yttrium-90, with its long-range beta
emission, is better suited for bulky disease. However, promising
results have been observed using 90Y-RIT in the consolidation set-
ting in patients in partial response (PR) or complete response (CR)
after induction therapy (14). Radionuclides such as 131I or 177Lu
with shorter-range energy emissions should be more favorable
in the setting of minimal residual disease (MRD). In this MRD
clinical setting, biodistribution and tumor dosimetry are more
favorable, tumor cells are less hypoxic and more radiosensitive
(15), and immunotherapy is more efficient (16).
Today, two products targeting CD20 have been approved: 131I-
tositumomab (Bexxar®; GlaxoSmithKline), and 90Y-ibritumomab
tiuxetan (Zevalin®, Spectrum Pharmaceuticals, Henderson, NV,
USA). 131I-tositumomab is available in the United States, and 90Y-
ibritumumab is approved in Europe, the United States, Asia, and
Africa. RIT can be integrated in clinical practice using non-ablative
activities for treatment of patients with relapsed or refractory FL
or as consolidation after induction chemotherapy in front-line
treatment in FL patients. Different RIT protocols are assessed in
clinical trials in FL or other lymphoma subtypes: myeloablative
or HD treatment, RIT as consolidation after chemotherapy to tar-
get MRD, RIT in first-line treatment, fractionated RIT and other
MAbs especially targeting antigens other than CD20. Moreover,
personalized dosimetry protocols are proposed to better predict
dose-effect relationships.
RIT OF NHL IN CLINICAL PRACTICE
ADMINISTRATION SCHEMES
Bexxar® and Zevalin® are administered 6–8 days after a pre-
dose of cold MAb, respectively 2× 450 mg of tositumomab and
2× 250 mg of rituximab, to improve biodistribution and tumor
targeting. The whole therapy requires only two outpatient visits.
No dosimetry study is required for Zevalin®. When a dosime-
try study is performed for research purposes, the first dose of
cold MAb is injected with 5 mCi of 111In-ibritumomab tiuxetan.
The injected activity depends on body weight and platelet count.
The therapeutic dose is 0.4 mCi/kg (14.8 MBq/kg) (0.3 mCi/kg,
11.1 MBq/kg, in patients with a platelet count of 100,000–
149,000/mm3) to a maximum total activity of 32 mCi (1,184 MBq)
(17). Bexxar® is delivered after a dosimetry study to identify
patients whose biodistribution profiles preclude administration
of the therapeutic step, and to adapt therapeutic activity to whole-
body clearance of the radiolabeled MAb. Whole-body clearance
is determined by a series of three scans recorded after infusion
of 5 mCi of 131I-tositumomab. This dosimetry study allows deter-
mination of the injected therapeutic activity required to deliver a
whole-body dose of 65–75 cGy. It has been demonstrated that if all
patients had been injected with a standard dose of 40.7 MBq/kg,
half of them would have been under or overdosed according to the
whole-body clearance studies (18).
EFFICACY
Despite the lack of phase III studies to clearly define the role of
RIT in the management of B lymphoma in the era of rituximab-
based therapy,RIT efficacy in B lymphoma has been demonstrated,
with the likelihood of providing a durable response. In a study of
143 patients with relapsed or refractory FL or transformed B-cell
NHL, Zevalin® appeared more efficient than rituximab, with the
OR and CR rates significantly higher with Zevalin® (80 vs. 56%,
p= 0.002, and 30 vs. 16%, respectively, p= 0.04) (87). Patients
refractory to rituximab had a 74% OR and those with thrombo-
cytopenia 83% OR (87, 19). Mean time to progression (TTP) in
responders was 12.6 months. OR was observed in 50% of patients
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with bulky lymphoma. Chemotherapy, administered in patients
treated with RIT, was not associated with higher toxicity (20). In a
meta-analysis involving relapsed NHL patients treated with Zeval-
in® in four clinical trials, long-term responses (TTP> 12 months)
were seen in 37% of patients (21). At a median follow-up time of
53.5 months, the median TTP was 29.3 months. A third of these
patients had been treated with at least three previous therapies,
and 37% of them had not responded to their last therapy. The
estimated 5 year-OS was 53% for all patients treated with Zevalin®
and 81% for long-term responders.
Using Bexxar®, a long-term meta-analysis performed on 250
heavily pre-treated patients with indolent lymphoma treated in
five clinical trials, OR rates ranged from 47 to 68% and CR
rates from 20 to 38% (22). For the durable response popula-
tion, the median duration of response was 45.8 months and the
median duration of response had not been reached at 5 years
for those who had achieved a CR. Interestingly, patients who
showed durable responses had poor prognostic characteristics
(bone marrow involvement in 41%, bulky disease ≥5 cm in 49%,
and transformed histology in 23%).
In 2011 The International Radioimmunotherapy Network
(RIT-N) reported on the long-term observational data from 467
Zevalin® -treated patients with an observation time of at least
12 months outside the randomized clinical studies (23). Lym-
phoma subtype was documented for all patients at initial diag-
nosis: 58% FL, 20% DLBCL, 14% MCL, and less than 10% other
subtypes. Most patients had stage IV disease according to the Ann
Arbor Classification, and 15% had bone marrow infiltration. FL
patients received RIT as consolidation in 45% of cases, after first-
and second-line therapy, and for recurrence in 37.7% of cases, in
second- and more than third-line therapy. For patients with other
lymphoma subtypes, RIT was predominantly used as consolida-
tion (69%) in first-line therapy and in recurrence (13%) in second-
and more than third-line therapy. Response was documented for
448 patients (260 with FL and 188 with other lymphoma subtypes).
Three hundred and thirty-six (75%) patients achieved a CR and
70 (16%) a partial remission (PR). The CR rate in FL patients was
73%, as compared with 77% in other lymphoma subtypes. The dif-
ference in CR rates and progression-free survival (PFS) between
the pivotal studies and the RIT-N study could be explained by
a different patient selection, with treatment of patients earlier in
clinical practice than in pivotal studies. Previously,Emmanouilides
et al. showed that earlier injection of Zevalin® lead to better out-
comes (24). As compared to patients treated at least at second
relapse, patients treated at first relapse had a higher OR rate (86 vs.
72%, p= 0.051) and CR rate (49 vs. 28%, p= 0.004) and longer
TTP (12.6 vs. 7.9 months, p= 0.038). Similarly, higher OR and
CR rates were observed in patients treated by Bexxar® at first or
second relapse (25).
In an interesting recent review on treatment of lymphoma
by RIT, Illidge regretted the low implementation of RIT in cur-
rent clinical practice (26). Despite the unique non-cross-reactive
mechanisms of action of RIT with proven high clinical efficacy in
patients resistant to chemotherapy and rituximab (probably the
most active approaches ever developed for NHL), RIT has failed
to be adopted by hemato-oncologists. Both 131I-tositumomab
and 90Y-ibritumomab have demonstrated high clinical efficacy in
heavily pre-treated populations, including patients with disease
refractory to both chemotherapy and rituximab underlying their
unique mechanisms of action of RIT.
SAFETY
Hematological toxicity is the major side effect of RIT, and depends
on bone marrow involvement and prior treatment (27–29). After a
0.4 mCi/kg of Zevalin®, grade-4 neutropenia, thrombocytopenia,
and anemia occurred in 30, 10, and 3% of patients, respectively.
Using Bexxar®, grade-4 neutropenia, thrombopenia, and anemia
were observed in 17, 3, and 2%, respectively. Nadir occurred
7–9 weeks after Zevalin® injection, and 4–6 weeks after Bexxar®
injection. In the long-term analysis of the international RIT-
N, no significant difference was observed between patients with
FL and patients with other lymphoma histologies (23). Time
to complete recovery of blood count (hemoglobin> 12 g/dL,
platelets> 150,000/µL, and leukocytes> 4,300/µL) had a median
of 99 days for FL patients and 97 days for patients with other lym-
phoma subtypes. For hemoglobin, the nadir was reached in a
median of 47.5 days for FL and 42 days for patients with other lym-
phoma subtypes, for platelets, in a median 35 days for FL and other
lymphoma subtypes and for leukocytes, in a median of 40 days for
FL and 38 days for patients with other lymphoma subtypes.
Non-hematological toxicity is generally low, including asthenia,
anorexia, fever, nausea, headache, chills, arthralgia, and myal-
gia. Allergic reactions have been observed during MAb infusion,
in particular after the first rituximab injection before Zeval-
in®. It is important to highlight that RIT is well tolerated by
older patients and represents a strong treatment choice in this
group of patients. Immunogenicity with human anti-mouse and
human anti-chimeric antibody production was observed, rang-
ing from 1 to 63% between studies. The immunogenicity risk was
significantly higher in previously untreated patients (30).
Secondary myelodysplastic syndrome (MDS) or acute myel-
ogenous leukemia were reported in 1–3% of cases (23, 27, 28, 31).
The risk appears to be increased in patients previously treated
by several lines of chemotherapy or radiotherapy. However, no
causal relationship between RIT and subsequent MDS has been
established, and there is ongoing debate about the role of prior
therapy (i.e., fludarabine) as the causative agent rather than RIT
itself (31). Moreover, prior RIT has not posed a limitation to
subsequent stem-cell collection and transplantation (20, 32). A
cytological and genetic analysis of bone marrow could be proposed
for heavily pre-treated patients prior to beginning RIT. In the long-
term analysis of the international RIT-N, the rate of secondary
solid tumors was 0.8%, including breast cancer, prostate cancer,
multiform glioblastoma, and non-small-cell lung cancer (23).
Finally, it is important to highlight that toxicity due to RIT is rel-
atively low compared with the side-effects of anthracycline-based
combination chemotherapy that includes significant early toxicity
with vomiting, alopecia, neutropenia, infection, neuropathy, and
late toxicity with cardiomyopathy, neuropathy.
HIGH-DOSE TREATMENT
These approaches require autologous or allogeneic SCT and con-
sist of injecting RIT myeloablative activity or a combination of
standard or escalated activity of RIT with HD chemotherapy. The
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rationale of HD approaches is to deliver curative radiation doses to
tumor sites while limiting exposure to normal organs. The ratio-
nale of RIT combined with chemotherapy is to obtain a synergistic
effect between radio-sensitizing chemotherapy and radiation.
HD RIT
Administration of HD RIT without chemotherapy could be bene-
ficial in aggressive NHL, which probably requires higher absorbed
doses than indolent NHL, and for patients older than 60 years,
which are often denied potentially curative HD chemotherapy
because of the risk of excessive treatment-related morbidity and
mortality. Liu et al. reported results of RIT using activities of
10.4–29.0 GBq (280–785 mCi) of 131I-tositumomab in 29 patients
with relapsed B-cell NHL (33). The OR was 86%, with 79% CR
and, with a median follow-up of 42 months, the estimated OS and
PFS rates 68 and 42%, respectively. The non-hematopoietic dose-
limiting toxicity (DLT) was reversible cardiopulmonary insuffi-
ciency, which occurred in two patients at doses ≥27 Gy to the
lungs. Late side-effects included renal insufficiency in one patient,
and functional cardiac impairment in another. Two patients
developed second malignancies, but none have developed MDS.
In 2007, Gopal et al. reported their experience with HD 131I-
tositumomab activity in 24 patients older than 60 years with
relapsed B-cell NHL (34). About 12–42.7 GBq (328–1,154 mCi)
were injected to deliver 25–27 Gy to the critical normal organ
receiving the highest radiation dose. Autologous SCT was per-
formed approximately 2 weeks after therapy. The estimated 3 year
OS and PFS rates were 59 and 51%, respectively, with a median
follow-up of 2.9 years. There were no treatment-related deaths,
and only two patients experienced grade-4 non-hematological
toxicity.
Feasibility of HD Zevalin® (0.8–1.5 mCi/kg, 57–150 mCi, 2.1–
5.55 GBq) was also reported in 13 refractory NHL patients (eight
DLBCL, one FL, three MCL, and one transformed MZL) (35).
Median age was 68 years (28–73), with a median of three prior
therapy courses including HD chemotherapy (1–6). The dosime-
try study showed acceptable calculated absorbed doses to normal
organs. Two patients were treated at a lower activity level because
of elevated liver uptake. Infections and liver toxicity were observed,
but no pulmonary, cardiac or renal toxicity. About 8 of 13 patients
showed objective response with six CR and two PR. One patient
still in CR for MCL developed a MDS 2 years after treatment. Thus,
HD RIT could be considered as an effective treatment modality
for resistant/refractory NHL considered unsuitable for aggressive
salvage treatments.
HD TREATMENT COMBINING RIT AND CHEMOTHERAPY
Regimens using escalated doses of RIT
Press et al. conducted a phase I/II trial to estimate the maxi-
mum tolerated dose (MTD) of 131I-tositumomab that could be
combined with etoposide and cyclophosphamide, followed by
autologous SCT, in 52 patients with relapsed B-cell NHL (36). The
MTD of 131I-tositumomab that could be safely combined with
60 mg/kg etoposide and 100 mg/kg cyclophosphamide was calcu-
lated to deliver 25 Gy to critical normal organs. The estimated OS
and PFS at 2 years was 83 and 68%, respectively. These findings
compare favorably with those in a non-randomized control group
of patients who underwent transplantation, external-beam total-
body irradiation (TBR), and etoposide and cyclophosphamide
therapy during the same period (OS of 53% and PFS of 36% at
2 years), even after adjustment for confounding variables in a mul-
tivariate analysis. Interestingly, survival was improved in aggressive
and indolent NHL.
This approach was also validated in 16 patients with relapsed or
refractory MCL (37). The enrolled patients had received a median
of three prior treatments. The median activity of iodine-131
was 510 mCi (18.87 GBq). There were no therapy-related deaths.
Among the 11 patients with conventionally measurable disease at
the time of treatment, the respective CR and OR were 91 and 100%.
Fifteen patients remained alive, and 12 without progression at 6–
57 months after transplantation. OS at 3 years after transplantation
was estimated at 93% and PFS at 61%.
Today, a standard HD schedule before transplantation includes
carmustine, etoposide, cytarabine, and melphalan (BEAM). Win-
ter et al. assessed a Z-BEAM regimen using escalated doses
of Zevalin® (900–1700 cGy to critical organs, 0.3–1.2 mCi/kg)
in 44 patients with chemo-refractory NHL (55% DLBCL, 16%
Richter, 16% MCL, 11% low-grade) (38). Two DLTs occurred at
the 1700 cGy dose level. One heavily pre-treated patient devel-
oped MDS 291 days after the treatment. The 3-year OS and PFS
rates were 52 and 37%, respectively. For dosimetry-based trials,
1500 cGy to the critical organ was the recommended dose (around
0.8 mCi/kg of Zevalin®). Outcomes were encouraging given the
high-risk patient population.
Regimens using standard doses of RIT combined with high-dose
chemotherapy
BEAM was also assessed when combined with standard dose of
RIT. Vose et al. determined, in a phase I trial, the maximum
outpatient dose of 131I-tositumomab (up to 0.75 Gy total-body
dose) combined with BEAM followed by autologous SCT for the
treatment of chemotherapy-resistant relapsed or refractory NHL
(39). Twenty-three patients received 0.30–0.75 Gy total-body dose
of RIT. The CR rate was 57% and the OR rate 65%. Short-
term and long-term toxicities were similar to historical control
patients treated with BEAM alone. With a median follow-up of
38 months (range, 27–60 months), OS was 55%, and event-free
survival (EFS) 39%.
The combination of BEAM with standard dose of 90Y-RIT has
also been assessed. Shimoni et al. reported the safety and outcome
following standard-dose Zevalin® (0.4 mCi/kg) followed by HD
BEAM and autologous SCT in 23 patients (median age 55 years;
ranging from 35 to 66) with chemo-refractory NHL (15 DLBCL, 7
Richter, 1 MCL), either primary refractory or in refractory relapse
(40). Rituximab followed by Zevalin® were given on day-14 and
HD BEAM started on day-6. Of the 21 patients evaluated, 11
achieved CR and 9 achieved PR, 5 of whom converted to CR with
additional radiation therapy (overall CR rate 76%). The estimated
2 year OS and PFS were 67 and 52%, respectively. The day-100
rate of treatment-related mortality was 9% (95% CI, 2–33%), and
the 2-year cumulative incidence of relapse was 31% (95% CI, 17–
57%). Extensive prior therapy (>3 lines), high LDH and IPI score
at ASCT, bulky disease, and progression during last chemotherapy
were risk factors for reduced survival.
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Krishnan et al. conducted another study combining Zeval-
in® with HD chemotherapy and autologous SCT using BEAM in
patients with non-Hodgkin’s lymphoma and who were considered
ineligible for TBR because of older age or prior radiotherapy (41).
Eligible patients had CD20 positive refractory FL (4), poor-risk
MCL (13), DLBCL (20), or transformed lymphoma (4). Median
age was 60 years (range, 19–78 years). With a median follow-up
of 18.4 months, the global estimated 2 year-overall OS was 88.9%
(89.7% for DLBCL, 84.6 for MCL, and 85% for FL, respectively).
Adverse events were similar to those seen historically with HD
BEAM alone. More recently and in order to compare RIT and
TBR-based conditioning regimens of ASCT, Krishnan et al. con-
ducted a matched-cohort analysis in 92 DLBCL patients treated
with either Z-BEAM (0.4 mCi/kg of Zevalin) or TBI-based con-
ditioning regimens (fractionated TBI at 1200 cGy, with etoposide
and cyclophosphamide) (42). OS at 4 years was 81.0% for the
Z-BEAM and 52.7% for the TBI group (p= 0.01). There was
no significant difference in the 4-year cumulative incidence of
relapse/progression between Z-BEAM or TBI regimen (40.4 and
42.1%, respectively), whereas the non-relapse mortality was signif-
icantly higher in the TBI group (0% compared with 15.8% for TBI
at 4 years), underlying the potentially lower toxicity of Z-BEAM.
In a recent prospective multicenter study, Shimoni et al. also
demonstrated that standard-dose Zevalin® (0.4 mCi/kg) com-
bined with BEAM HD chemotherapy was safe and possibly more
effective than BEAM alone as a conditioning regimen for ASCT
in 43 patients with relapsed/refractory aggressive non-Hodgkin
lymphoma (31 DLBCL, three mediastinal lymphomas and nine
transformed FL) (43). There was no difference in engraftment
kinetics between the two study arms. There was no significant
added toxicity with the Z-BEAM regimen although there was
a trend for more mucositis and more serious infections in this
group. The 2-year PFS was 59 and 37% in the Z-BEAM and
BEAM arms, and the 2-year OS was 91 and 62%, respectively.
Interestingly, multivariate analysis identified BEAM alone as one
of the poor prognostic factors. The results of this randomized
study confirmed all the previously reported observations that the
addition of Zevalin® to HD chemotherapy is safe and not associ-
ated with excess toxicity. In order to definitively validate Z-BEAM
regimen as a standard of care for ASCT, larger multicentric phase
III clinical studies should be undertaken to better assess survival
in homogenous groups of NHL patients, previously treated with
rituximab-containing front-line and second-line chemotherapy.
Regimens using standard doses of RIT combined with allogeneic
SCT
Recently, reduced-intensity conditioning (RIC) regimens have
been developed to permit elderly patients or patients with co-
morbidities, contraindicated for HD myeloablative chemotherapy,
to allow allogeneic SCT. In order to increase the efficacy of the
allogeneic graft, new strategies have been employed to increase
the activity of RIC by adding Zevalin® in the conditioning reg-
imen. Bethge et al. designed a study to evaluate the feasibility
of adding RIT to allo-SCT (44). Forty patients with low-grade
advanced NHL were enrolled in this phase 2 study combining RIT
using standard dose of Zevalin® with RIC using fludarabine and
2 Gy TBI followed by allogeneic SCT. Combination of RIT with
RIC seemed not to increase the toxicity in comparison to the pre-
vious experience in patients conditioned with fludarabine/2 Gy
TBI alone. The study concluded that combined use of RIT with
RIC was feasible with acceptable toxicity, even in elderly and
heavily pre-treated patients. Another study performed by Gopal
et al. also examined the combined use of RIT with RIC (flu-
darabine and 2 Gy TBR) for a non-myeloablative allo-SCT (45).
Dosimetry was studied on day-21 before standard dose of Zeval-
in®. Forty patients were included: 18 with indolent lymphoma, 14
with DLBCL (7 de novo and 7 aggressive transformations), and
8 with MCL. At a median follow-up of 30 months, the estimated
2 year OS and PFS were 54 and 31%, respectively. Multivariate
analysis revealed that patients with aggressive histology had poor
OS and PFS when compared with indolent histology (p< 0.01).
This prospective phase II trial concluded that the combined use
of RIT with RIC was safe and feasible and was able to induce
objective remissions in the majority of these high-risk patients,
which were otherwise not previously considered candidates for
either standard myeloablative or non-myeloablative transplanta-
tions, including patients with chemo-resistant, bulky disease, or
aggressive histology.
RIT AS CONSOLIDATION AFTER INDUCTION THERAPY
In the RIT-N analysis, a high efficacy in both FL and other lym-
phoma subtypes was observed when RIT was applied as part of
the first-line treatment, as consolidation after induction therapy,
to target MRD (23). The FIT randomized phase III trial showed
the benefits of Zevalin® as consolidation in previously untreated
FL patients (14). After completing induction therapy, patients
were randomized to receive either standard dose of Zevalin®
(n= 208) or no further treatment (n= 206). Induction therapies
included CVP/COP (n= 106), CHOP and CHOP-like (n= 183),
fludarabine combinations (n= 22), chlorambucil (n= 39), and
rituximab-chemotherapy combinations (n= 59). A high conver-
sion rate from PR to CR of 77% was observed after RIT, leading
to a high CR rate of 87% after RIT. Interestingly, the same CR
rate was obtained after RIT in all subgroups of induction therapy,
despite the difference in CR rate between the initial chemotherapy
regimens. The quality of the response improvement was associated
with increase of PFS of more than 2 years in the RIT-consolidation
arm as compared to the control arm. However, no significant
increase of PFS was observed in the sub-group of patients receiv-
ing a rituximab-based therapy as induction, probably because of
the statistically small number of patients treated with this regimen.
RIT could be considered as an alternative to rituximab for com-
bination with CHOP. The Southwest Oncology Group (SWOG)
and Cancer and Leukemia Group B recently reported the results
of the phase III randomized intergroup protocol (SWOG S0016)
that enrolled 554 patients with previously untreated, advanced-
stage FL to compare six cycles of R-CHOP at 3 week intervals
with six cycles of CHOP followed by consolidation with tosi-
tumomab/iodine I-131 tositumomab (46). However, no benefits
were observed in the RIT arm: after a median follow-up period of
4.9 years, the 2-year estimated PFS was 76% on the CHOP-R arm
and 80% on the CHOP-RIT arm (p= 0.11), and the 2-year esti-
mated OS 97% on the CHOP-R arm and 93% on the CHOP-RIT
arm (p= 0.08).
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The fact that no benefit of RIT has been demonstrated as an
alternative to rituximab combined with CHOP, or as consolidation
after 6–8 cycles of R-CHOP, constitutes a limit in the development
of RIT in an era in which R-CHOP has substantially improved
outcome and represented a therapeutic standard. Moreover, ritux-
imab maintenance treatment after R-chemotherapy was recently
demonstrated to improve the relapse-free survival in a large phase
III study (47). Several reports suggested comparable efficacy of
RIT consolidation and rituximab maintenance; however these
two approaches have not been compared in a randomized trial.
Ideally, rituximab and RIT should be considered as complemen-
tary approaches with possible additive or synergistic effect. This
could be achieved by performing a, randomized phase III trials
to compare maintenance by rituximab versus consolidation by
RIT or maintenance by rituximab versus consolidation by RIT+
maintenance by rituximab, following induction with R-CHOP.
The use of RIT as consolidation might also allow reduced
chemotherapy cycle number. Leonard et al. reported in 2005,
in 35 previously untreated FL patients, the efficacy of three
abbreviated courses of fludarabine followed by, 6–8 weeks later,
tositumomab and 131I-tositumomab (48). After fludarabine, 31
(89%) of 35 patients responded, with three (9%) of 31 patients
achieving a CR. After the full regimen of fludarabine and 131I-
tositumomab, all 35 patients responded, with 30 patients (86%)
achieving a CR. The 5-year estimated PFS rate was 60%. Baseline
FLIPI was significantly associated (p= 0.003) with PFS. About 10
of 13 patients (77%) with baseline bone marrow Bcl-2 positiv-
ity demonstrated molecular remissions at 12 months. Toxicities
were manageable and mainly hematological. Two of 35 patients
(6%) developed human anti-murine antibodies (HAMA) after
RIT. The authors concluded that this sequential treatment regi-
men was highly effective as a front-line therapy for FL, particu-
larly for low- or intermediate-risk FLIPI patients. Zevalin® also
has been assessed as consolidation after Rituximab with short
duration chemotherapy (49). Forty-one patients with previously
untreated FL received rituximab for four consecutive weeks, fol-
lowed by three cycles of rituximab combined with either CHOP
(88%) or CVP (cyclophosphamide/vincristine/prednisone; 12%).
To complete treatment, all patients received Zevalin® 4–6 weeks
after the final dose of chemotherapy. After completion of short-
course rituximab/chemotherapy, 95% had objective responses,
with 30% clinical CR. The clinical CR rate increased to 72% fol-
lowing RIT. After a median follow-up of 67 months, the estimated
5 year PFS and OS rates were 64 and 96%, respectively. Zeval-
in® was well tolerated after short-course rituximab/chemotherapy
and the authors concluded that a high CR rate and a long PFS
were obtained using this scheme. Definitive demonstration of
improved efficacy versus rituximab/chemotherapy alone requires
a randomized study.
Radioimmunotherapy consolidation has been also assessed
in other B-NHL subtypes and represents an especially relevant
therapeutic alternative in elderly patients. In DLBCL patients,
although the R-CHOP combination as standard regimen has led
to improved outcomes, there is a group of poor-risk patients with
a lower chance of being cured with standard R-CHOP, thus need-
ing an alternative treatment strategy. Zinzani et al. published in
2010 the results of a phase II study assessing the efficacy and safety
of Zevalin® following four cycles of R-CHOP21, in 55 high-risk
elderly (age≥ 60 years) patients with previously untreated DLBCL
(50). Forty-eight of the 55 patients received RIT. The OR rate for
the entire treatment regimen was 80%, including 73% CR. About
8 of the 16 patients (50%) who achieved less than a CR after R-
CHOP improved their remission status after RIT. With a median
follow-up of 18 months, the 2-year PFS was estimated to be 85%,
with a 2-year OS of 86%. RIT toxicity was relatively high,consisting
of grade 3–4 neutropenia in 23 patients and thrombocytopenia in
15 patients. These results suggested that RIT could be considered
as a promising alternative approach in high-risk elderly patients
who are not candidates to SCT.
Recently, Smith et al. reported the results of a Phase II study
of the Eastern Cooperative Oncology Group Study assessing R-
CHOP in untreated MCL patients (51). The rational was based on
three points: (a) MCL is predominantly a disease of patients older
than 60 years of age, very often contraindicated for HD chemother-
apy, (b) R-CHOP as initial therapy for untreated MCL had a high
response rate, but remissions are not durable, and (c) RIT of MCL
seemed to induce a high response rate but very short TTP (52).
About 56 patients were eligible: 48 patients were treated with
Zevalin® standard dose whereas three received a 25% reduced-
dose. The design required 52 eligible patients to detect a 50%
improvement in the median time to treatment failure compared
with that reported for six cycles of R-CHOP. For the 56 analyzed
patients the overall response rate at completion of therapy was
82%: RIT improved quality of response in 22 patients: 16 patients
converted from PR to CR/CRu, three patients from stable disease
to CR/CRu, and three patients from stable disease to PR. With
a median follow-up of 72 months, the median time to treatment
failure was 34.2 months and the estimated 1.5 year time to treat-
ment failure 69%. These results were better than those previously
reported in patients treated by six cycles of R-CHOP and there was
no unexpected toxicity after RIT.
Even if the potential of RIT as consolidation after R-CHOP
induction therapy were to be confirmed in randomized large phase
III studies, these different studies suggest that RIT is a relevant
option as consolidation therapy in different subtypes of B-NHL, in
order to decrease the number of chemotherapy courses in elderly
patients or as an alternative of STC in high-risk patients.
RIT MONOTHERAPY IN FIRST-LINE TREATMENT
Radioimmunotherapy can also be considered alone in front-line
treatment. As shown by Emmanouilides et al., an injection of
Zevalin® earlier in the course of the disease leads to better out-
comes (24). Indeed, the best results of non-myeloablative RIT
administered alone (without chemotherapy) have been obtained
as first-line treatment of FL (30). A single 1 week course of
131I-tositumomab therapy, as initial treatment, can induce pro-
longed clinical and molecular remissions. Seventy-six patients
with stage III or IV FL received as initial therapy a single course
of 131I-tositumomab therapy. Ninety-five percent of the patients
responded, including 75% with a CR. The use of PCR to detect
rearrangement of the bcl2 gene showed molecular responses in
80% of assessable patients who had a clinical CR. After a median
follow-up of 5.1 years, the actuarial 5 year PFS for all patients was
59%, with a median PFS of 6.1 years. Of 57 patients who had a CR,
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40 remained in remission for 4.3–7.7 years. Hematological toxicity
was moderate, with no patient requiring transfusions or growth
factors. No case of MDS has been observed. The immunization
rate was higher than the rate observed in patients treated later in
the course of disease.
Preliminary results of a European multicenter study using frac-
tionated RIT Zevalin® as a front-line therapy for patients with FL
grade I–IIIa with at least one criteria of high tumor burden or B
symptoms were presented at The American Society of Hematol-
ogy in 2011 (53). Treatment consisted of two doses of Zevalin®
(11.1 MBq/kg) given 8–12 weeks apart. Patients with greater than
20% bone marrow involvement with lymphoma received four
weekly infusions of Rituximab (375 mg/m2) and proceeded to
fractionated RIT only if a repeat bone marrow biopsy demon-
strated clearing of lymphoma with less than or equal to 20%
involvement. 74 patients with a median age of 61 years (28–80),
including 58 with stage III–IV disease were included. About 55
patients received the two-planned Zevalin® infusion whereas 17
received only one infusion. At a median follow-up of 1.52 years
(range 0.13–3.69 years) the PFS was 67%, 20/74 patients had pro-
gressed. The ORR was 97.1% with 64% of CR/CRu. The most
common toxicity was hematologic and reversible. One case of
MDS was diagnosed 26 months after treatment.
Recently, Scholz et al. also evaluated, in an international multi-
center phase II clinical trial, the efficacy, and feasibility of Zevalin®
as first-line treatment for FL (54). Fifty-nine patients, median
age 66 years (range, 51–83 years), were included. Treatment indi-
cation resulted from B symptoms, grade 3a, organ compression
or infiltration, rapid growth and/or bulky disease. The ORR at
6 months after RIT was 87%, with 41% of the patients achieving
CR, 15% CRu, and 31% PR. Median PFS was 25.9 months (95% CI,
18.2–33.7 months). RIT was well tolerated and the most common
toxicity was hematologic and reversible. Patients with increased
LDH may not benefit from RIT as much as patients with normal
LDH do.
In these two studies assessing monotherapy with Zevalin® in
first-line treatment, the OR was superior to the response rate
reported in chemotherapy-naive patients treated with four courses
of rituximab monotherapy. Ghielmini et al. reported in this popu-
lation a 67% response rate with only 9% CR in 64 patients receiving
four courses of rituximab (55). RIT should be considered as an
attractive therapeutic option in elderly patients or in patients with
comorbidity.
FRACTIONATED RIT
The advantages of fractionated delivery of external radiation
therapy may also apply to RIT (85). RIT produces a less uni-
form tumor dose distribution than external radiation therapy,
because of the inability of MAbs to penetrate uniformly through-
out the tumor, resulting in some tumor regions under-dosed. An
absorbed dose heterogeneity ranging up to 400% was measured
using quantitative autoradiography, in the Raji B-cell lymphoma
animal model injected with anti-HLA-DR 131I-Lym-1 MAb (56).
DeNardo et al. reported the following advantages for fraction-
ated RIT: more uniform MAb distribution and radiation dose,
patient-specific radionuclide and radiation dose, control toxicity
by titration of an individual patient, reduced toxicity, increased
injected activity, tumor radiation and efficacy, and prolongation
of tumor response (57).
Several clinical studies have shown the benefits of fractionated
RIT in patients with B-cell hemopathies. DeNardo et al. reported
toxicity and efficacy of 131I-Lym-1 in 25 patients with relapsing
NHL and five patients with chronic lymphocytic leukemia (58):
19/25 NHL patients had bone marrow involvement, with exten-
sive marrow malignancy in seven cases, and all five patients with
CLL had diffuse bone marrow infiltration. Patients were treated
with doses of 30 or 60 mCi of 131I-Lym-1, 2–6 weeks apart; 11 of
the 30 patients completed the intended 300 mCi. Treatment was
interrupted by hematological toxicity in three patients and the
development of HAMA in three; a 57% response rate was obtained.
Based on this strategy, a dose escalation trial was designed to define
the MTD of the first two of a maximum of four injections of 131I-
Lym-1 given 4 weeks apart (58). 131I-Lym-1 was escalated from
40 to 100 mCi/m2. The non-myeloablative MTD for each of two
doses of 131I-Lym-1 was 100 mCi/m2 in patients with less than
25% bone marrow involvement. All three entries in this patient
cohort achieved CR.
The use of chimeric or humanized MAbs facilitates fractiona-
tion by reducing the immunization rate. Illidge et al. published the
results of a protocol assessing four weekly infusions of 375 mg/m2
rituximab, followed by two fractions of 131I-rituximab, preceded
by a 100-mg/m2 predose of rituximab, in relapsed indolent NHL
(59). Induction therapy with rituximab significantly increased the
effective half-life of 131I-rituximab, and high serum levels of rit-
uximab after induction therapy correlated with increased effective
half-life of the radiolabeled MAb. The pharmacokinetics of ritux-
imab have previously been studied and found to be influenced by
the availability of CD20 (the“antigen sink”), with the greater num-
ber of CD20-binding sites in bulky disease causing sequestration of
rituximab and decreasing concentrations in the serum compart-
ment. A negative correlation was observed between splenic and
lymph node volumes and the rituximab serum levels after initial
rituximab dosing. Interestingly, patients with large initial tumor
burdens exhibited a greater than 40% increase in 131I-rituximab’s
effective half-life between delivery of the first and the second
fractions. The most likely explanation for these observations was
the tumor responses observed clinically after the first therapeutic
injection. The OR rate was 94%, with 50% CR. The median TTP
was 20 months, significantly longer than for the last chemotherapy
course. Moreover, fractionated 131I-rituximab provided cumula-
tive whole-body doses of more than 120 cGy, approximately 60%
greater than those obtained previously after a single course of RIT,
without significant hematologic toxicity. These results demon-
strated the high potential of fractionated injections for increasing
RIT efficacy for NHL treatment.
PRETARGETED RIT OF LYMPHOMA
Because of the long residence time of antibodies in the circula-
tion and their efficient transfer to bone marrow, the DLT in RIT is
hematological in most cases. The pretargeting approach that uses
a low molecular weight as a carrier for radioactivity and unlabeled
antibody conjugates, injected in advance, to target the radioactivity
to tumors was geared at reducing non-tumor tissue exposure (60).
Pretargeting may be achieved using a variety of methods. Two of
www.frontiersin.org July 2013 | Volume 3 | Article 177 | 7
Bodet-Milin et al. RIT of B-cell non-Hodgkin’s lymphoma
them have been documented in large numbers of preclinical and
clinical studies. One uses bispecific anti-tumor/anti-hapten anti-
bodies to target low molecular weight radiolabeled haptens. The
other uses antibody-avidin conjugates to target radiolabeled biotin
derivatives. In both cases, improvements have been necessary to
prevent excess circulating antibody conjugates to trap the radio-
labeled molecule in the circulation. Antibody-avidin pretargeting
thus generally includes a chase step before injection of the radiola-
beled biotin derivative, while bispecific antibody pretargeting uses
bivalent haptens that bind more tightly to bispecific antibody mol-
ecules attached to the target cell surface than to the excess bispecific
antibody present in the circulation (60). With both approaches,
tumor to non-tumor target activity uptake ratios are improved
as compared to directly labeled antibodies and pretargeting was
shown to be able to deliver tumoricidal irradiation doses. The fea-
sibility of pretargeting in the clinic has been documented in several
instances and it has been shown that it can increase OS in progres-
sive, metastatic medullary thyroid carcinoma, a radioresistant and
chemo-resistant solid tumor (61).
For lymphoma, and more generally in hematological diseases,
it is believed that tumor cells are more readily accessible to radio-
labeled antibodies and often more radiosensitive and, as a result,
that sophisticated targeting approaches such as pretargeting are
not required to achieve tumor control. Indeed, even though pre-
targeting approaches to lymphoma were proposed a long time
ago in mice (62, 63), the literature remains poor in terms of
reports of pretargeted RIT clinical trials of lymphoma. In one
study of 10 patients with relapsed or refractory B-cell NHL,
seven were treated with a streptavidin-conjugated anti-CD20 anti-
body (rituximab) to sequester yttrium-90-labeled DOTA-biotin
(1.11 or 1.85 GBq/m2) after clearing excess streptavidin conjugate
by an injection of biotin-N-acetyl-galactosamine (64). Radio-
labeled biotin was shown to localize in the tumor, with rapid
excretion of unbound radioactivity. Little non-hematologic tox-
icity was observed and hematological toxicity was limited and
transient. Three complete and one PR were observed. However,
humoral immune responses to streptavidin were demonstrated
in 6 of 10 patients. In another phase I trial, a tetrameric single-
chain anti-CD20-streptavidin fusion protein was used to target
yttrium-90-labeled DOTA-biotin in NHL patients, again with a
clearing step (65). In this study, the 15 patients received only
560 MBq/m2 of 90Y-DOTA-biotin that rapidly localized in tumor
or was excreted in the urine. There were two complete remissions
(90 and 325 days) and one PR (297 days) and hematologic toxicity
was acceptable. However, patient immune responses against the
antibody-streptavidin conjugate was frequent.
It is clear that the remarkable efficacy of directly labeled
antibodies against lymphoma makes pretargeting less attractive
here than in solid tumors. However, pretargeting could make
activity escalation possible and could in principle achieve very
high response rates without bone marrow ablation, as more
recent preclinical studies suggest (66). Another perspective cre-
ated by pretargeting is the possibility of using short-lived alpha-
emitting radionuclides in consolidation therapy to eradicate MRD
because of the fast tumor activity accretion provided by this
technology (67).
TARGET ANTIGENS OTHER THAN CD20
The development of a RIT approaches against antigens other than
CD20 targeted by rituximab appears relevant, especially if RIT
is applied in combination with rituximab-based therapy, offer-
ing the possibility of targeting populations of cells not expressing
CD20, or not responding to anti-CD20 cold MAbs. Several anti-
gens have been tested: CD21, CD22, CD37, and HLA DR (68). Both
radiolabeled anti-CD22 epratuzumab and anti-HLA-DR (Lym-1)
MAb have shown efficacy in patients who have failed chemother-
apy, either with low-grade or aggressive forms of NHL (58, 60,
69). CD22 is a transmembrane glycoprotein expressed on mature
B-cells but not expressed on stem cells or plasma cells, and func-
tions in B-cell regulation/activation. CD22 is highly expressed
across malignant B-cell histologies. Epratuzumab, has good fea-
tures for RIT because it is humanized, internalized by target
cells, stably labeled using DOTA (1,4,7,10-tetraazacyclododecane-
N,N ′,N ′′,N ′′-tetraacetic acid),and administered without a loading
dose of cold antibody, at variance with Zevalin® or Bexxar®.
Sharkey et al. reported the results of a phase I/II trial assess-
ing 90Y-epratuzumab in patients with relapsing B lymphoma (70).
Patients had a pre-therapy imaging study with 111In-epratuzumab
1 week before 90Y-epratuzumab injection, starting at an activity
level of 0.185 GBq/m2 in patients who had prior HD chemother-
apy (Group 2), and at 0.370 GBq/m2 in patients who did not have
a prior stem-cell transplantation (SCT) (Group 1), with esca-
lation in 0.185 GBq/m2 increments. Radiation absorbed doses
to liver, lungs, and kidneys averaged 0.55± 0.13, 0.28± 0.06,
and 0.38± 0.07 mGy/MBq, respectively, with 0.14± 0.02 and
0.23± 0.04 mGy/MBq delivered to the whole-body and red mar-
row, respectively. Tumor doses ranged from 1.0 to 83 mGy/MBq
for a 0.5-g lesion (median= 7.15 mGy/MBq). Anti-tumor effects
were seen in both indolent and aggressive NHL. The data also
suggest that anti-tumor responses of potentially equal magnitude
can occur irrespective of tumor targeting and tumor size. Hence,
tumor response did not correlate with the radiation dose delivered
or with the tumor being visualized by external imaging. These
observations should not been interpreted that there was a minor
effect of targeting, but probably could be explained by the role of
immunological mechanisms in tumor response after RIT. In this
study, an immunization was detected in only two of 16 patients.
After demonstrating, in a single-center trial, the safety and
preliminary efficacy of 90Y-epratuzumab administered at low
5 mCi/m2 (185 MBq/m2) doses repeated over several weeks (71),
a multicenter phase I/II study was designed to assess fraction-
ated 90Y-epratuzumab in NHL relapsing patients (72). Unlabeled
epratuzumab was co-administered each week for a 1.5 mg/kg
protein dose. The first week, 111In-epratuzumab was co-infused,
with targeting of at least one known disease site by gamma-
camera imaging 3–6 days later required to continue weekly 90Y-
epratuzumab infusions. Patients with prior SCT underwent sep-
arate dose escalation, starting with 92.5 MBq/m2 weekly doses
escalated in 2.5 mCi/m2 increments. Non-SCT patients started
with 185 MBq/m2 weekly doses and 2.5 mCi/m2 increments that
increased to 5.0 mCi/m2 to reach the highest dose level. Sixty-
four patients (32 males, 32 females) were enrolled at five institu-
tions in France and Germany between 2001 and 2007, including
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35 FLs, 14 MCL, 11 DLBCL, and four patients with marginal
zone lymphoma. These patients had one to five prior therapies
(median: 2), including an anti-CD20-based therapy in 52 cases
and a bone marrow transplant in 17 cases. The total 90Y treat-
ment dose ranged from 0.185 to 1.665 GBq/m2, with comparable
numbers treated at≤0.37 (N = 17),>0.37–0.74 (N = 13),>0.74–
1.11 (N = 16), and >1.11 GBq/m2 (N = 18). Even at the highest
total 90Y dose of 1.665 MBq/m2 studied, grade 3–4 hematological
toxicities were manageable with support in patients with <25%
bone marrow involvement, and transient with 2–3 weeks median
recovery to Grade 1. The overall OR rate was 62% (48% CR/CRu),
including all NHL subtypes [FL: 74% (62%); MCL: 50% (21%);
DLBCL: 30% (20%); marginal zone: 100% (100%)]; and in poor-
risk patients [unresponsive to last therapy: 72% (56%); bulky
disease: 60% (35%); elevated LDH: 56% (44%); positive bone
marrow: 46% (31%); prior SCT: 41% (29%)]. For FL without
prior SCT, response rates increased with total 90Y dose, with 92%
CR/CRu at the highest dose levels (>1.11 MBq/m2). Patients with
CR/CRu achieved long-lived responses continuing up to 5 years,
including 24.6 month median PFS for 12 FL patients receiving
>1.11 MBq/m2 total 90Y dose. This study demonstrated that frac-
tionated RIT with 90Y-epratuzumab achieved high rates of durable
CRs with manageable toxicity in previously treated lymphoma
patients. While fractionation may have improved the diffusion
of subsequent doses, the favorable efficacy and safety observed
here even at HDs also could reflect antibody internalization with
improved 90Y residence time, the more stable DOTA radio-labeling
method used, or the lack of neutralizing antibodies induced with
this humanized antibody.
Targeting of antigens other than CD20 appears particularly
interesting in the context of consolidation therapy after rituximab-
based therapy and the high injected activity achieved with frac-
tionated 90Y-epratuzumab suggested the benefits of using this
approach in DLBCL probably requiring higher dose than indo-
lent lymphoma. A French phase II trial sponsored by the LYSA
group assessed front-line treatment using fractionated RIT with
90Y-epratuzumab as consolidation therapy after courses of R-
CHOP in previously untreated elderly (age >60 years) patients
presenting with stage I/II bulky or stage III/IV DLBCL. Two infu-
sions of 90Y-epratuzumab (2× 555 MBq/m2, 7 days apart) were
delivered 8 weeks after R-CHOP (73). Seventy-five patients have
been accrued prospectively, 57 (76.0%) with Ann Arbor stage
III/IV disease; 61/75 (81.2%) received the RIT. RIT toxicity con-
sisted of grade 3–4 hematologic toxicity in 51/61 patients (83.6%).
RIT’s severe non-hematologic toxicity consisted of grade-4 gas-
trointestinal in one patient (1.6%) and grade-4 infection in three
(4.9%). Two patients (2.6%) developed MDS 5–20 months after
RIT. The OR rate after 6×R-CHOP14 was 94.6% (71/75); 52
patients (69.3%) achieved CR/CRu and 19 (25.3%) had a PR. In
an intention-to-treat analysis, CR/CRu rate after 6×R-CHOP14
followed by RIT was 72.0% (N = 54). At a median follow-up of
24 months (range 1–46), 18 patients experienced lymphoma pro-
gression and/or a related death, yielding an estimated 2 year EFS of
73.3% (60.7–82.5%) and an estimated 2 year OS of 83.2% (71.4–
90.4%). For the 61 patients who received six courses of R-CHOP
followed by 90Y-epratuzumab, ORR was 91.8% (56/61), 50 patients
(81.9%) achieving CR/CRu. This phase II study clearly shows
that fractionated RIT with 90Y-epratuzumab as a consolidation
therapy after 6×R-CHOP14 is feasible and tolerable in elderly
untreated DLBCL patients with advanced disease. RIT improved
response status observed after 6×R-CHOP14. EFS data achieved
with R-CHOP plus RIT compare favorably with those achieved
with R-CHOP alone in the same patient population.
Another important perspective is the clinical evaluation of
dual-targeted antibody/radioantibody therapy (74, 75). Com-
bining an unconjugated anti-CD20 antibody therapy with a
radioimmunoconjugate binding to a non-competing antigen
might improve responses by allowing optimal uptake of each
agent. Mattes et al. showed in an animal model the benefit of tar-
geting a non-competing antigen for consolidation after RIT using
90Y-epratuzumab tetraxetan. Tumor response and survival rates
were improved when a consolidation using anti-CD20 veltuzumab
was delivered after anti-CD22 RIT (74). Moreover, Sharkey et al.
(75) demonstrated that injection of cold MAb after the radioac-
tivity dose provided higher efficacy than injection before RIT, and
that the amount of predose of cold MAb should be minimized.
These preclinical data raise important questions, and a re-
examination of RIT in the treatment of NHL was proposed by
R. Sharkey, O. Press and D. Goldenberg in Blood in 2009 (86). The
authors emphasized that in RIT clinical practice, nearly 900 mg
of unlabeled anti-CD20 IgG antibody is predosed to the patient
before the anti-CD20 90Y or 131I RIT. Combining a naked anti-
CD20 therapy with a radioimmunoconjugate binding to a non-
competing antigen might improve responses by allowing optimal
uptake of each agent. Preclinical models indicated that careful
consideration should be given to predosing when using compet-
ing antibodies, but that consolidation anti-CD20 therapy enhances
the efficacy of radioimmunoconjugate therapy.
OPTIMIZATION OF INJECTED ACTIVITY USING DOSIMETRY
Pre-RIT dosimetry studies should allow the pharmacokinetics
of each patient to be assessed and allow the injected activity to
be adapted. Dosimetry studies performed before Bexxar® injec-
tion showed large variability between patients, requiring injection
of around 1.85–5.55 GBq of Bexxar® to deliver a 75 cGy whole-
body dose. Indeed, many patients are probably under-treated with
the standard activity of 14.8 MBq/kg of Zevalin®. No dose-effect
relationship has been clearly demonstrated in clinical studies,
but patients had been heavily pre-treated. Dosimetry of RIT in
first- line treatment should allow a better analysis of a dose-effect
relationship.
Moreover, immuno-PET using iodine-124 or yttrium-86 could
improve quantitative imaging and biodistribution analysis of
Bexxar® and Zevalin®, respectively. Preclinical studies in mice
showed that 89Zr- and 88Y-Zevalin® had a very similar biodis-
tribution, implying that 89Zr-Zevalin®-PET might be well suited
for prediction of 90Y-Zevalin® biodistribution in a myeloablative
setting (76).
In principle, dosimetry is useful to optimize radiation deliv-
ery during treatment in order to avoid toxicities to critical organs
and to administer absorbed doses to tumors as highly as possible.
Although firmly established in external radiotherapy treatment,
this paradigm is not yet so settled in RIT. In NHL RIT, dosime-
try studies are performed more to avoid hematological toxicities
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rather than to estimate absorbed doses to targets, which are usu-
ally disseminated throughout the patient and often of small sizes,
particularly in residual diseases (77).
Dosimetry studies are mandatory with Bexxar® treatments.
Indeed, Wahl et al. showed that pharmacokinetics varied widely
from one patient to another and more importantly that bone mar-
row toxicities were correlated to the total-body radiation dose (78).
In contrast, no dosimetry study is required for Zevalin® treatment
as no toxicity/absorbed dose relationship was assessed during the
initial multicenter study (79).
Since then, recent publications have described better toxic-
ity/absorbed dose relationships. In a series of 58 FL patients treated
by Zevalin® RIT as a consolidation therapy after a first-line ther-
apy, Delaloye et al. conducted a dosimetry study, assessing bone
marrow absorbed dose using blood samples (80). The authors
clearly found a correlation between whole-body and bone marrow
absorbed doses with the PFS whereas no correlation was estab-
lished between both absorbed doses and hematological toxicity.
It is worth noticing that RIT was employed at an early stage of
the therapeutic course as opposed to the initial phase I/II study
where patients were heavily treated beforehand and probably suf-
fered from major bone marrow impairments. This suggests that
the sooner RIT is positioned along the therapeutic course, the
better it is to assess an absorbed dose/effect relationship.
This assumption was also supported by a recent dosimetry
study performed on 28 newly diagnosed FL patients treated by two
fractions of Zevalin® (81). Different bone marrow absorbed dose
calculation approaches were compared to hematological toxicity.
One main result was that blood samples were not able to predict
hematological toxicities on patients even with low BM involvement
(<20%) as opposed to image-based methods that clearly foresaw
those toxicities. Another interesting result was that quantification
based on 3D SPECT imaging afforded a better relationship than
2D whole-body imaging and echoed findings of He et al. (82).
Indeed, in this last publication, 2D whole-body and SPECT imag-
ing were also compared on 18 patients enrolled in clinical trial
of HD myeloablative Zevalin® therapy. The authors showed dif-
ferences in residence time as high as 18% for the dose-limiting
organ – the liver in this context.
This stresses an interesting point previously mentioned by
Sjögreen-Gleisner et al. (83). In this recent review of lymphoma
RIT dosimetry, the authors compared dosimetry results in light
of the approaches used in different publications and concluded
that there was a definite influence due to the dosimetry method-
ology used. This is not surprising of course, but does highlight
the importance of standardization of dosimetry procedures, and
advocates for the more widespread use of 3D SPECT/CT imaging
which will lead to the more robust approach.
As already mentioned, a much more challenging task and
goal would be to correlate tumor absorbed dose to therapeutic
response. Dewaraja et al. also used SPECT/CT imaging to per-
form a dosimetry study on 20 NHL patients treated with Bexxar®
RIT (84). They found an improved tumor absorbed dose-response
relationship once an equivalent uniform dose (EUB) that takes
into account the biological effect of the cold antibody was con-
sidered. Publications showing absorbed dose-response/toxicity
relationships are currently present even in NHL RIT therapy. In
this context, dosimetry should be performed with a high qual-
ity level in order to demonstrate a correlation between absorbed
dose-effect/toxicity relationships.
CONCLUSION
Clinical results show that RIT has significant efficacy, but moder-
ate response duration as a monotherapy in rituximab-refractory
recurrence of NHL. A higher therapeutic impact may be achieved
using RIT in HD myeloablative treatment, as consolidation after
chemotherapy-immunotherapy, or as a first-line treatment. Ran-
domized phase III clinical trials should be performed in naïve
or minimally treated patients to better identify the benefits and
the role of RIT in NHL in the era of rituximab based therapy.
Dosimetry studies and fractionated administration could probably
optimize the injected activity. Preclinical studies suggest the ben-
efits of dual-targeted antibody/radioantibody therapy, combining
an unconjugated anti-CD20 antibody therapy with a radioim-
munoconjugate binding to a non-competing antigen, such as
CD22.
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